Loading stock data…
IRWD
$4.44+0.32 (+7.64%)
Pre-Market$4.44+0.00 (+0.08%)· Last close May 1
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ironwood Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.44. The stock is currently 23% below its 52-week high of $5.78, remaining 58.0% above its 200-day moving average. Technical signals show neutral RSI of 66 and bullish MACD crossover, explaining why IRWD maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 66) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.44
Potential Downside
38.3%
Whystock Fair Value$2.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$640.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.20
Beta
Defensive asset. Lower volatility than the S&P 500.
0.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-9.17%
Volume
Today's trading volume
1.74M
Recent News
Nektar (NKTR) Moves 18.3% Higher: Will This Strength Last?
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is one of the 7 best small-cap drug manufacturing stocks to buy according to hedge funds. On February 26, Citizens analyst Jason Butler maintained an Outperform rating on Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD). The firm increased its price target from $8 to $10. Citizens noted that the company’s fourth-quarter results were in […]
IRWD Stock Down 14% in a Month: Time to Buy, Sell or Hold the Stock?
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
Why Is Ironwood (IRWD) Down 13.9% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.